Simulations Plus Launches Version 2.0 of PKPlus™
February 01 2018 - 8:30AM
Business Wire
Major update to preclinical and clinical
trial data analysis software addresses user requests
Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of
simulation and modeling software and consulting services for
pharmaceutical development from earliest discovery through all
phases of clinical trials, today announced the launch of version
2.0 of PKPlus, a major update to its software for analysis of
preclinical and clinical trial data.
Mark Pflieger, product manager for PKPlus, said: “From our
initial release of PKPlus Version 1.0 in August 2016, we have paid
careful attention to the feedback given by our customers and
prospects. With their guidance and suggestions, and in close
collaboration with our colleagues at Cognigen, we now have PKPlus
Version 2.0, which contains many new features and
improvements.”
New features & enhancements of PKPlus 2.0 include:
- Non-Parametric Superposition (NPS)
- Compartmental multi-dose
simulation
- Command line version (for fast,
automated validation checks)
- The ability to save map/report settings
for use in other projects
- Improvements to plotting and custom
reports
- Additional workflow refinements
John DiBella, president of the Lancaster division for
Simulations Plus, added: “PKPlus continues to be the most
affordable, commercially supported PK modeling platform in the
marketplace, and we have decided with this new release to offer it
to academic institutions at no cost to invest in the next
generation of researchers who will be advancing the science of
simulation and modeling. PKPlus v2.0 meets the requirements of a
validated PK software, combining sophistication and ‘plug and play’
simplicity, at a fraction of the cost of competing tools. As more
scientists work with the program, we’ll continue to listen and
respond to update features and capabilities.”
Simulations Plus will host a webinar on Tuesday, February 20 at
8 a.m. PST (Los Angeles) to discuss the exciting new features in
PKPlus 2.0. Please register here:
www.simulations-plus.com/webinars/.
About Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of drug discovery
and development software as well as a leading provider of both
preclinical and clinical pharmacometric consulting services for
regulatory submissions and quantitative systems pharmacology models
for drug-induced liver injury and nonalcoholic fatty liver disease.
The company is a global leader focused on improving the ways
scientists use knowledge and data to predict the properties and
outcomes of pharmaceutical, biotechnology, and chemical agents. Our
software is licensed to and used in the conduct of drug research by
major pharmaceutical, biotechnology, chemical, and consumer goods
companies and regulatory agencies worldwide. Our innovations in
integrating new and existing science in medicinal chemistry,
computational chemistry, pharmaceutical science, biology, and
physiology into our software have made us the leading software
provider for physiologically based pharmacokinetic modeling and
simulation. For more information, visit our website at
www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 – With the exception of historical
information, the matters discussed in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Our actual future results could differ significantly
from those statements. Factors that could cause or contribute to
such differences include, but are not limited to: our ability to
maintain our competitive advantages, acceptance of our new software
products as well as improved versions of our existing software by
our customers, the general economics of the pharmaceutical
industry, our ability to finance growth, our ability to continue to
attract and retain highly qualified technical staff, and a
sustainable market. Further information on our risk factors is
contained in our quarterly and annual reports and filed with the
U.S. Securities and Exchange Commission.
Follow us on Twitter | LinkedIn
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180201005479/en/
Simulations Plus Investor
RelationsMs. Renee Bouche,
661-723-7723renee@simulations-plus.comorHayden IRMr. Cameron Donahue,
651-653-1854cameron@haydenir.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Sep 2023 to Sep 2024